Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain
Primary Purpose
Osteoarthritis, Pain
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Placebo Gel
OLT1177 Gel
Sponsored by

About this trial
This is an interventional treatment trial for Osteoarthritis
Eligibility Criteria
Inclusion Criteria:
- Age 45 to 80 years old, inclusive
Clinical diagnosis of osteoarthritis in one target knee based on the following American College of Rheumatology (ACR) criteria:
- Knee Pain
At least 1 of 3:
- Age > 50 years
- Morning stiffness lasting < 30 minutes
- Crepitus on motion
- Osteophytes on radiograph
- Symptoms associated with osteoarthritis of the knee (including pain) for ≥ 6 months prior to Screening
- Knee pain associated with osteoarthritis, which required NSAID or other therapy for ≥ 15 days during the preceding month
- Radiographic evidence of osteoarthritis by Kellgren-Lawrence classification with a rating of Grade 2 or 3 in the target knee (does not include borderline Grade 2), as confirmed by the Sponsor's designated rheumatologist through radiographic review of x-ray(s) taken no more than 1 year prior to the Screening visit. (Sharpening of the tibial spine is not considered to be an osteophyte) (See Appendix 4 for additional details)
- Meets pain assessment entry criteria as defined by Sponsor's pain eligibility algorithm and calculated by the study Interactive Web Response System
- No clinically significant change in physical activity and/or therapy for the past 3 months
- Able to provide written informed consent prior to initiation of any clinical trial-related procedures; and willing and able, in the opinion of the Investigator, to comply with all requirements of the clinical trial for the duration of the trial (such requirements include, but are not limited to: attending all study visits, refraining from elective surgery or extensive travel during participation)
Exclusion Criteria:
General
Women of childbearing potential, or men whose sexual partner(s) is a woman of childbearing potential may not be entered into the study if:
- They are or intend to become pregnant (including use of fertility drugs) during the study
- They are nursing
- They are not using an acceptable, highly effective method of contraception until all follow-up procedures are complete. (Acceptable, highly effective forms of contraception are defined as: oral contraception, intrauterine device, systemic [injectable or patch] contraception, double barrier methods, naturally or surgically sterile, strict abstinence or partner has been sterilized. If hormonal-based birth control is being used, subject or subject's sexual partner(s) must be on a stable-dose for ≥ 3 months prior to the Baseline visit and maintained at the same dosing level throughout the 9-week clinical trial.)
- Body Mass Index (BMI) over 40
- A history of osteoarthritis symptoms that are completely non-responsive to non-steroidal anti-inflammatory drugs (NSAIDs) at the discretion of the Investigator
- Planned change (increase or decrease) in subject's level of physical activity (e.g., aerobic or anaerobic exercise) during the 6-week Treatment Period following randomization
- Enrollment in any trial and/or use of any Investigational Drug or device within the immediate 30-day period prior to the Baseline visit
- Enrollment in any study previously sponsored by Olatec Industries LLC, specifically Study OLT1177-01 or OLT1177-02
Pain Related
- Does not meet pain assessment entry criteria as defined by Sponsor's pain eligibility algorithm and calculated by the study Interactive Web Response System
- Clinically significant joint (other than the knee) or general pain at Baseline, at the discretion of the Investigator
Musculoskeletal Related
- Clinically significant, excessive effusion heat and/or redness in the target knee as determined by the Investigator
- Knock-kneed or bow-legged, as defined by a valgus or varus deformity of ≥ 15 degrees
- Radiographic evidence of osteoarthritis by Kellgren-Lawrence classification with a rating of Grade 0, 1 or 4 in the target knee, as confirmed by the Sponsor's designated rheumatologist through radiographic review of x-ray(s) taken no more than 1 year prior to the Screening visit (sharpening of the tibial spine is not considered to be an osteophyte)
- Documented history of clinically significant pain associated with osteoarthritis of the spine or hips, at the discretion of the Investigator
- Significant anterior knee pain due to diagnosed isolated patella-femoral syndrome or chondromalacia
- Clinically significant medio-lateral and/or anterior-posterior instability, at the discretion of the Investigator
- Open surgery of the target knee within the prior year or surgery to the contralateral knee or other weight-bearing joint within the prior year, if at the discretion of the Investigator it would interfere with the study. If subject had open surgery more than one-year prior, Sponsor's designated rheumatologist must confirm that such surgery did not have any negative impact or consequence to the target knee (e.g., deformity of angle to the bone, bone on bone, locking joints, etc.)
- Arthroscopic surgery of the target knee within the prior six months
- Any acute or chronic injury, other than osteoarthritis in the target knee, that will be treated during the trial with any medication not allowed during the Treatment Period
- Prior surgery of the target knee requiring insertion of a medical device or surgical hardware (e.g., screws)
- Any major trauma or injury (including sports injuries) to the target knee in the past 12 months
- Documented history of inflammatory joint disease, including but not limited to: rheumatoid arthritis, gout, pseudogout, Paget's disease, psoriatic arthritis, ankylosing spondylitis, chronic inflammatory disease (e.g., colitis), fibromyalgia (diagnosed in accordance with ACR criteria, as applicable), articular fracture, ochronosis, acromegaly, hemochromatosis, Wilson's disease, primary osteochondromatosis, heritable disorders (e.g., hypermobility) or collagen gene mutations
- Any planned interventional and/or surgical procedure during the 6-week Treatment Period following randomization
Concomitant Conditions, Diseases, Medications/Therapies and Medical History Related
- Any use of Rescue Medication within 24 hours prior to the Baseline visit or use of any other pain medication within 7 days prior to Baseline visit
- Uncontrolled hypertension, defined as blood pressure ≥ 150/95 mmHg
- A history of uncontrolled and untreated diabetes mellitus with an HbA1c level > 8; or blood sugar levels that are outside of the normal range and HbA1c level > 8 is subsequently confirmed
- Any inflammatory skin condition over the target knee application area
- Use of any prohibited concomitant medications/therapies during the 7-day Washout Period or planned use of any prohibited concomitant medications/therapies during the 6 week Treatment Period
- Use of intraarticular or intramuscular steroids in the target knee within the previous 3 months or in any other joint within the previous 30 days
- Use of intraarticular hyaluronate in the target knee within the previous 6 months or in any other joint within the previous 30 days
- Current substance abuse or history of chronic substance abuse within the past year, or prior chronic substance abuse (including alcoholism and/or addiction to pain medications) that is determined at the discretion of the Investigator as likely to interfere with trial assessments or recur during the trial
- Use of any systemic (oral or parenteral) corticosteroids within the prior month
- Uncontrolled psychiatric conditions (e.g., mania, depression, anxiety, substance dependence of any kind) that would impair the subject from safely participating in the trial, including completing any protocol requirements
- Evidence of cognitive impairment including dementia that may interfere with subject's ability to complete daily pain diaries requiring recall of average pain level in the past 24 hours
- Significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological or neurological disease or prior surgery that may interfere with the subject successfully completing the trial, including completing any protocol requirements as determined by the Investigator
- History of or known positive for HIV, Hepatitis B surface antigen (HBsAg) or antibodies to Hepatitis C Virus (HCV)
- Diagnosed with any form of cancer within the past 5 years, except for treated basal cell or squamous cell carcinoma of the skin
- Any other medical conditions, diseases or prior surgeries that in the opinion of the Investigator would impair the subject from safely participating in the trial and/or completing any protocol requirements
- Active infection within 3 days of the Baseline visit
Sites / Locations
- Achieve Clinical Research, LLC
- Clinical Research Consulting, LLC
- Avail Clinical Research
- Health Awareness, Inc.
- Sunrise Medical Research, Inc.
- International Clinical Research - US, LLC
- Miami Research Associates, LLC
- Best Clinical Trial, LLC
- Healthcare Research Network, Inc.
- Omega Medical Research
- Clinical Trials of South Carolina
- Coastal Carolina Research Center, Inc
- Charlottesville Medical Research Center, LLC
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Placebo Gel
OLT1177 Gel
Arm Description
6 mL of Placebo Gel administered TID for 6 weeks
6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
Outcomes
Primary Outcome Measures
Pain on Movement
Subjects will record their level of Pain on Movement in the target knee on a 100-mm VAS scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the average amount of your study knee pain while moving during your daily activities within the last 24 hours?'
Secondary Outcome Measures
Current Knee Pain
After completing a walk of approximately 50 feet, subjects will record their level of Current Knee Pain in the target knee on a 100-mm Visual Analog Scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the amount of your study knee pain right now?'
WOMAC Pain Subscale
The WOMAC NRS3.1 OA Index is a validated, segregated, multidimensional, self-administered index with three independent dimensions: pain, physical function and stiffness. It is comprised of 24 questions to be answered by the subject. The pain subscale consists of 5 questions; the physical function subscale consists of 17 questions; and the joint stiffness subscale consists of 2 questions.
WOMAC Physical Function Subscale
The WOMAC NRS3.1 OA Index is a validated, segregated, multidimensional, self-administered index with three independent dimensions: pain, physical function and stiffness. It is comprised of 24 questions to be answered by the subject. The pain subscale consists of 5 questions; the physical function subscale consists of 17 questions; and the joint stiffness subscale consists of 2 questions.
Global Rating of Disease
Subjects will complete the assessment on a 100-mm Visual Analog Scale (with anchors 0=very good; 100=very poor) in response to the question, 'Considering all the ways osteoarthritis affects you, how well are you doing?'
Current Knee Pain
After completing a walk of approximately 50 feet, subjects will record their level of Current Knee Pain in the target knee on a 100-mm Visual Analog Scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the amount of your study knee pain right now?'
WOMAC Stiffness Subscale
The WOMAC NRS3.1 OA Index is a validated, segregated, multidimensional, self-administered index with three independent dimensions: pain, physical function and stiffness. It is comprised of 24 questions to be answered by the subject. The pain subscale consists of 5 questions; the physical function subscale consists of 17 questions; and the joint stiffness subscale consists of 2 questions.
Pain on Movement (VAS, in-clinic)
Subjects will record their level of Pain on Movement in the target knee on a 100-mm VAS scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the average amount of your study knee pain while moving during your daily activities within the last 24 hours?'
Pain on Movement (11-point NRS, diary)
All evaluations will be on the 11-point Numerical Rating Scale (with anchors 0=no pain; 100=extreme pain) and in response to the following instructions: Please put an "X" over the one number below that best describes your average study knee pain while moving during your daily activities since you woke up this morning.
Use of Rescue Medication
Subjects will record the amount, time/date and dose of Rescue Medication use throughout the trial.
Short Form 12v2 Health Survey
The SF-12v2 Health Survey is a multipurpose short-form (SF) general health survey comprised of 12 questions to measure functional health and well-being from the subject's perspective.
Full Information
NCT ID
NCT02104050
First Posted
March 28, 2014
Last Updated
October 2, 2017
Sponsor
Olatec Therapeutics LLC
1. Study Identification
Unique Protocol Identification Number
NCT02104050
Brief Title
Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain
Official Title
A Phase 2b Randomized, Double-Blind, Vehicle-Controlled, Repeat-Dose, Multi- Center, Efficacy and Safety Clinical Trial of Topically Applied OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With Osteoarthritis of the Knee Following Cessation of Pain Therapy
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
April 2014 (undefined)
Primary Completion Date
August 2015 (Actual)
Study Completion Date
August 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Olatec Therapeutics LLC
4. Oversight
5. Study Description
Brief Summary
The objectives of this trial are to investigate the efficacy and safety of six weeks of treatment with OLT1177 Gel in subjects with moderate to severe pain associated with osteoarthritis of the knee following cessation of pain therapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Pain
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
202 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo Gel
Arm Type
Placebo Comparator
Arm Description
6 mL of Placebo Gel administered TID for 6 weeks
Arm Title
OLT1177 Gel
Arm Type
Experimental
Arm Description
6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo Gel
Intervention Description
6 mL of Placebo Gel administered TID for 6 weeks
Intervention Type
Drug
Intervention Name(s)
OLT1177 Gel
Intervention Description
6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
Primary Outcome Measure Information:
Title
Pain on Movement
Description
Subjects will record their level of Pain on Movement in the target knee on a 100-mm VAS scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the average amount of your study knee pain while moving during your daily activities within the last 24 hours?'
Time Frame
Baseline to Week 6
Secondary Outcome Measure Information:
Title
Current Knee Pain
Description
After completing a walk of approximately 50 feet, subjects will record their level of Current Knee Pain in the target knee on a 100-mm Visual Analog Scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the amount of your study knee pain right now?'
Time Frame
Baseline (pre-dose) to Baseline (50-min post-dose)
Title
WOMAC Pain Subscale
Description
The WOMAC NRS3.1 OA Index is a validated, segregated, multidimensional, self-administered index with three independent dimensions: pain, physical function and stiffness. It is comprised of 24 questions to be answered by the subject. The pain subscale consists of 5 questions; the physical function subscale consists of 17 questions; and the joint stiffness subscale consists of 2 questions.
Time Frame
Baseline to Weeks 2, 4 and 6
Title
WOMAC Physical Function Subscale
Description
The WOMAC NRS3.1 OA Index is a validated, segregated, multidimensional, self-administered index with three independent dimensions: pain, physical function and stiffness. It is comprised of 24 questions to be answered by the subject. The pain subscale consists of 5 questions; the physical function subscale consists of 17 questions; and the joint stiffness subscale consists of 2 questions.
Time Frame
Baseline to Weeks 2, 4 and 6
Title
Global Rating of Disease
Description
Subjects will complete the assessment on a 100-mm Visual Analog Scale (with anchors 0=very good; 100=very poor) in response to the question, 'Considering all the ways osteoarthritis affects you, how well are you doing?'
Time Frame
Baseline to Weeks 2, 4 and 6
Title
Current Knee Pain
Description
After completing a walk of approximately 50 feet, subjects will record their level of Current Knee Pain in the target knee on a 100-mm Visual Analog Scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the amount of your study knee pain right now?'
Time Frame
Baseline to Hours 2-6
Title
WOMAC Stiffness Subscale
Description
The WOMAC NRS3.1 OA Index is a validated, segregated, multidimensional, self-administered index with three independent dimensions: pain, physical function and stiffness. It is comprised of 24 questions to be answered by the subject. The pain subscale consists of 5 questions; the physical function subscale consists of 17 questions; and the joint stiffness subscale consists of 2 questions.
Time Frame
Baseline to Weeks 2, 4 and 6
Title
Pain on Movement (VAS, in-clinic)
Description
Subjects will record their level of Pain on Movement in the target knee on a 100-mm VAS scale (with anchors 0=no pain; 100=extreme pain) in response to the question, 'How do you estimate the average amount of your study knee pain while moving during your daily activities within the last 24 hours?'
Time Frame
Baseline to Weeks 2, 4 and 6
Title
Pain on Movement (11-point NRS, diary)
Description
All evaluations will be on the 11-point Numerical Rating Scale (with anchors 0=no pain; 100=extreme pain) and in response to the following instructions: Please put an "X" over the one number below that best describes your average study knee pain while moving during your daily activities since you woke up this morning.
Time Frame
Baseline through Week 6
Title
Use of Rescue Medication
Description
Subjects will record the amount, time/date and dose of Rescue Medication use throughout the trial.
Time Frame
Baseline through Week 6
Title
Short Form 12v2 Health Survey
Description
The SF-12v2 Health Survey is a multipurpose short-form (SF) general health survey comprised of 12 questions to measure functional health and well-being from the subject's perspective.
Time Frame
Baseline to Weeks 2, 4 and 6
Other Pre-specified Outcome Measures:
Title
Physical Examination: Number of subjects with clinically significant changes in Physical Examination in major body systems (HEENT, Neck, Cardiovascular, Abdominal, Respiratory, Musculoskeletal, Extremities Skin or Other)
Time Frame
Baseline through Week 8
Title
Vital Signs: Change from Baseline in Heart Rate (beats per minute)
Time Frame
Baseline through Week 8
Title
Vital Signs: Change from Baseline in Supine Diastolic Blood Pressure [mmHg]
Time Frame
Baseline through Week 8
Title
Vital Signs: Change from Baseline in Supine Systolic Blood Pressure [mmHg]
Time Frame
Baseline through Week 8
Title
Vital Signs: Change from Baseline in Body Temperature (axillary) [°C]
Time Frame
Baseline through Week 8
Title
Vital Signs: Change from Baseline in respiration rate (respirations per minute)
Time Frame
Baseline through Week 8
Title
Number of Adverse Events
Time Frame
Screening through Week 8
Title
Number of Serious Adverse Events
Time Frame
Screening through Week 8
Title
Number of Treatment Emergent Adverse Events
Time Frame
Baseline through Week 8
Title
Percent of Subjects experiencing Adverse Events
Time Frame
Screening through Week 8
Title
Percent of Subjects experiencing Serious Adverse Events
Time Frame
Screening through Week 8
Title
Percent of Subjects experiencing Treatment Emergent Adverse Events
Time Frame
Baseline through Week 8
Title
Safety Labs: Hematology
Description
Blood will be drawn for hematology laboratory analysis
Time Frame
Baseline through Week 8
Title
Safety Labs: Chemistry
Description
Blood will be drawn for chemistry laboratory analysis
Time Frame
Baseline through Week 8
10. Eligibility
Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 45 to 80 years old, inclusive
Clinical diagnosis of osteoarthritis in one target knee based on the following American College of Rheumatology (ACR) criteria:
Knee Pain
At least 1 of 3:
Age > 50 years
Morning stiffness lasting < 30 minutes
Crepitus on motion
Osteophytes on radiograph
Symptoms associated with osteoarthritis of the knee (including pain) for ≥ 6 months prior to Screening
Knee pain associated with osteoarthritis, which required NSAID or other therapy for ≥ 15 days during the preceding month
Radiographic evidence of osteoarthritis by Kellgren-Lawrence classification with a rating of Grade 2 or 3 in the target knee (does not include borderline Grade 2), as confirmed by the Sponsor's designated rheumatologist through radiographic review of x-ray(s) taken no more than 1 year prior to the Screening visit. (Sharpening of the tibial spine is not considered to be an osteophyte) (See Appendix 4 for additional details)
Meets pain assessment entry criteria as defined by Sponsor's pain eligibility algorithm and calculated by the study Interactive Web Response System
No clinically significant change in physical activity and/or therapy for the past 3 months
Able to provide written informed consent prior to initiation of any clinical trial-related procedures; and willing and able, in the opinion of the Investigator, to comply with all requirements of the clinical trial for the duration of the trial (such requirements include, but are not limited to: attending all study visits, refraining from elective surgery or extensive travel during participation)
Exclusion Criteria:
General
Women of childbearing potential, or men whose sexual partner(s) is a woman of childbearing potential may not be entered into the study if:
They are or intend to become pregnant (including use of fertility drugs) during the study
They are nursing
They are not using an acceptable, highly effective method of contraception until all follow-up procedures are complete. (Acceptable, highly effective forms of contraception are defined as: oral contraception, intrauterine device, systemic [injectable or patch] contraception, double barrier methods, naturally or surgically sterile, strict abstinence or partner has been sterilized. If hormonal-based birth control is being used, subject or subject's sexual partner(s) must be on a stable-dose for ≥ 3 months prior to the Baseline visit and maintained at the same dosing level throughout the 9-week clinical trial.)
Body Mass Index (BMI) over 40
A history of osteoarthritis symptoms that are completely non-responsive to non-steroidal anti-inflammatory drugs (NSAIDs) at the discretion of the Investigator
Planned change (increase or decrease) in subject's level of physical activity (e.g., aerobic or anaerobic exercise) during the 6-week Treatment Period following randomization
Enrollment in any trial and/or use of any Investigational Drug or device within the immediate 30-day period prior to the Baseline visit
Enrollment in any study previously sponsored by Olatec Industries LLC, specifically Study OLT1177-01 or OLT1177-02
Pain Related
Does not meet pain assessment entry criteria as defined by Sponsor's pain eligibility algorithm and calculated by the study Interactive Web Response System
Clinically significant joint (other than the knee) or general pain at Baseline, at the discretion of the Investigator
Musculoskeletal Related
Clinically significant, excessive effusion heat and/or redness in the target knee as determined by the Investigator
Knock-kneed or bow-legged, as defined by a valgus or varus deformity of ≥ 15 degrees
Radiographic evidence of osteoarthritis by Kellgren-Lawrence classification with a rating of Grade 0, 1 or 4 in the target knee, as confirmed by the Sponsor's designated rheumatologist through radiographic review of x-ray(s) taken no more than 1 year prior to the Screening visit (sharpening of the tibial spine is not considered to be an osteophyte)
Documented history of clinically significant pain associated with osteoarthritis of the spine or hips, at the discretion of the Investigator
Significant anterior knee pain due to diagnosed isolated patella-femoral syndrome or chondromalacia
Clinically significant medio-lateral and/or anterior-posterior instability, at the discretion of the Investigator
Open surgery of the target knee within the prior year or surgery to the contralateral knee or other weight-bearing joint within the prior year, if at the discretion of the Investigator it would interfere with the study. If subject had open surgery more than one-year prior, Sponsor's designated rheumatologist must confirm that such surgery did not have any negative impact or consequence to the target knee (e.g., deformity of angle to the bone, bone on bone, locking joints, etc.)
Arthroscopic surgery of the target knee within the prior six months
Any acute or chronic injury, other than osteoarthritis in the target knee, that will be treated during the trial with any medication not allowed during the Treatment Period
Prior surgery of the target knee requiring insertion of a medical device or surgical hardware (e.g., screws)
Any major trauma or injury (including sports injuries) to the target knee in the past 12 months
Documented history of inflammatory joint disease, including but not limited to: rheumatoid arthritis, gout, pseudogout, Paget's disease, psoriatic arthritis, ankylosing spondylitis, chronic inflammatory disease (e.g., colitis), fibromyalgia (diagnosed in accordance with ACR criteria, as applicable), articular fracture, ochronosis, acromegaly, hemochromatosis, Wilson's disease, primary osteochondromatosis, heritable disorders (e.g., hypermobility) or collagen gene mutations
Any planned interventional and/or surgical procedure during the 6-week Treatment Period following randomization
Concomitant Conditions, Diseases, Medications/Therapies and Medical History Related
Any use of Rescue Medication within 24 hours prior to the Baseline visit or use of any other pain medication within 7 days prior to Baseline visit
Uncontrolled hypertension, defined as blood pressure ≥ 150/95 mmHg
A history of uncontrolled and untreated diabetes mellitus with an HbA1c level > 8; or blood sugar levels that are outside of the normal range and HbA1c level > 8 is subsequently confirmed
Any inflammatory skin condition over the target knee application area
Use of any prohibited concomitant medications/therapies during the 7-day Washout Period or planned use of any prohibited concomitant medications/therapies during the 6 week Treatment Period
Use of intraarticular or intramuscular steroids in the target knee within the previous 3 months or in any other joint within the previous 30 days
Use of intraarticular hyaluronate in the target knee within the previous 6 months or in any other joint within the previous 30 days
Current substance abuse or history of chronic substance abuse within the past year, or prior chronic substance abuse (including alcoholism and/or addiction to pain medications) that is determined at the discretion of the Investigator as likely to interfere with trial assessments or recur during the trial
Use of any systemic (oral or parenteral) corticosteroids within the prior month
Uncontrolled psychiatric conditions (e.g., mania, depression, anxiety, substance dependence of any kind) that would impair the subject from safely participating in the trial, including completing any protocol requirements
Evidence of cognitive impairment including dementia that may interfere with subject's ability to complete daily pain diaries requiring recall of average pain level in the past 24 hours
Significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological or neurological disease or prior surgery that may interfere with the subject successfully completing the trial, including completing any protocol requirements as determined by the Investigator
History of or known positive for HIV, Hepatitis B surface antigen (HBsAg) or antibodies to Hepatitis C Virus (HCV)
Diagnosed with any form of cancer within the past 5 years, except for treated basal cell or squamous cell carcinoma of the skin
Any other medical conditions, diseases or prior surgeries that in the opinion of the Investigator would impair the subject from safely participating in the trial and/or completing any protocol requirements
Active infection within 3 days of the Baseline visit
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William Cunningham, MD, FAAD
Organizational Affiliation
Cu-Tech, LLC
Official's Role
Study Chair
Facility Information:
Facility Name
Achieve Clinical Research, LLC
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35216
Country
United States
Facility Name
Clinical Research Consulting, LLC
City
Milford
State/Province
Connecticut
ZIP/Postal Code
06460
Country
United States
Facility Name
Avail Clinical Research
City
DeLand
State/Province
Florida
ZIP/Postal Code
32720
Country
United States
Facility Name
Health Awareness, Inc.
City
Jupiter
State/Province
Florida
ZIP/Postal Code
33458
Country
United States
Facility Name
Sunrise Medical Research, Inc.
City
Lauderdale Lakes
State/Province
Florida
ZIP/Postal Code
33319
Country
United States
Facility Name
International Clinical Research - US, LLC
City
Sanford
State/Province
Florida
ZIP/Postal Code
32771
Country
United States
Facility Name
Miami Research Associates, LLC
City
South Miami
State/Province
Florida
ZIP/Postal Code
33143
Country
United States
Facility Name
Best Clinical Trial, LLC
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70115
Country
United States
Facility Name
Healthcare Research Network, Inc.
City
Hazelwood
State/Province
Missouri
ZIP/Postal Code
63042
Country
United States
Facility Name
Omega Medical Research
City
Warwick
State/Province
Rhode Island
ZIP/Postal Code
02886
Country
United States
Facility Name
Clinical Trials of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29406
Country
United States
Facility Name
Coastal Carolina Research Center, Inc
City
Mount Pleasant
State/Province
South Carolina
ZIP/Postal Code
29464
Country
United States
Facility Name
Charlottesville Medical Research Center, LLC
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22911
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain
We'll reach out to this number within 24 hrs